ID   MCF7-TamR
AC   CVCL_EG55
DR   cancercelllines; CVCL_EG55
DR   PRIDE; PXD001812
DR   Wikidata; Q54904464
RX   PubMed=26330541;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Deep phosphoproteome analysis.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 12
//
RX   PubMed=26330541; DOI=10.1074/mcp.M115.050484;
RA   Wu X.-Y., Zahari M.S., Renuse S., Nirujogi R.S., Kim M.-S., Manda S.S.,
RA   Stearns V., Gabrielson E.W., Sukumar S., Pandey A.;
RT   "Phosphoproteomic analysis identifies focal adhesion kinase 2 (FAK2)
RT   as a potential therapeutic target for tamoxifen resistance in breast
RT   cancer.";
RL   Mol. Cell. Proteomics 14:2887-2900(2015).
//